Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
33results about How to "Improved biodistribution" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Antibodies, analogs and uses thereof
InactiveUS20100092470A1Increased binding affinityImprove it biodistribution and retentionSugar derivativesAntibody ingredientsHeavy chainAntibody
Camelid and shark heavy chain only antibodies and their analogs are disclosed. Methods of making such antibodies and their analogs are also provided. Also provided are kits, and methods of using such antibodies and their analogs in diagnostics, prognostics, therapy, and simultaneous diagnosis and therapy.
Owner:ICB INT
Purification and preferential synthesis of binding molecules
ActiveUS20050163783A1Well formedImprove stabilityAntibacterial agentsSenses disorderDisulfide LinkageMedicinal chemistry
The instant invention describes methods of separating or preferentially synthesizing dimers which are linked via at least one interchain disulfide linkage from dimers which are not linked via at least one interchain disulfide linkage from a mixture comprising the two types of polypeptide dimers. These forms can be separated from each other using hydrophobic interaction chromatography. In addition, the invention pertains to connecting peptides that result in the preferential biosynthesis of dimers that are linked via at least one interchain disulfide linkage or that are not linked via at least one interchain disulfide linkage. The invention also pertains to compositions in which a majority of the dimers are linked via at least one interchain disulfide linkage or are not linked via at least one interchain disulfide linkage. The invention still further pertains to novel binding molecules, e.g., comprising connecting peptides of the invention.
Owner:BIOGEN MA INC
Targeted conjugates and particles and formulations thereof
InactiveUS20170151339A1Improve deliveryReduce deliveryPowder deliveryOrganic active ingredientsActive agentPharmaceutical formulation
Particles, including nanoparticles and microparticles, and pharmaceutical formulations thereof, comprising conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety via a linker have been designed which can provide improved temporospatial delivery of the active agent and / or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.
Owner:TVA (ABC) LLC
Controlled modulation of the pharmacokinetics and biodistribution of aptamer therapeutics
InactiveUS20060030535A1Reduce distributionReduce ratePowder deliveryActivity regulationControl mannerBiodistribution
Materials and methods are provided to modulate, in a controlled manner, the pharmacokinetic and biodistribution properties of nucleic acid aptamers, and to enhance their safety and efficacy properties as therapeutic agents.
Owner:ARCHEMIX CORP
Targeted Conjugates Encapsulated in Particles and Formulations Thereof
InactiveUS20140187501A1Improve permeabilityImprove retention effectOrganic active ingredientsPowder deliveryDiagnostic agentActive agent
Particles, including nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety via a linker have been designed which can provide improved temporospatial delivery of the active agent and / or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.
Owner:TVA (ABC) LLC
Sstr-targeted conjugates encapsulated in particles and formulations thereof
InactiveUS20160074526A1Improved biodistributionImprove permeabilityPowder deliveryOrganic active ingredientsDiagnostic agentMedicine
Particles, including nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety via a linker have been designed which can provide improved temporospatial delivery of the active agent and / or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.
Owner:TVA (ABC) LLC
RNA Modulating Oligonucleotides with Improved Characteristics for the Treatment of Neuromuscular Disorders
ActiveUS20150148404A1High affinityHigh melting temperatureNervous disorderSugar derivativesDiseaseInstability
The current invention provides an improved oligonucleotide and its use for treating, ameliorating, preventing, delaying and / or treating a human cis-element repeat instability associated genetic neuromuscular or neurodegenerative disorder.
Owner:VICO THERAPEUTICS BV
Compositions and methods for generating and screening adenoviral libraries
ActiveUS20090074658A1Promote generationReduce binding and infection rateUltrasonic/sonic/infrasonic diagnosticsVirusesDNAVirology
The present invention provides DNA libraries, libraries of viral clones and libraries of infectious viral particles and methods of generating and screening these libraries.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Stapled peptide conjugates and particles
InactiveUS20190365913A1Reduce deliveryImproved biodistributionPowder deliveryCell receptors/surface-antigens/surface-determinantsCancer preventionDiagnostic agent
Conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety via a linker, and particles comprising such conjugates have been designed which can provide improved temporospatial delivery of the active agent and / or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.
Owner:TVA (ABC) LLC
RNA Modulating Oligonucleotides with Improved Characteristics for the Treatment of Duchenne and Becker Muscular Dystrophy
ActiveUS20170029818A1High affinityHigh melting temperatureSplicing alterationMuscular disorderMuscular dystrophyBiochemistry
The current invention provides an improved oligonucleotide and its use for treating, ameliorating, preventing and / or delaying DMD or BMD.
Owner:BIOMARIN TECH BV
Targeted conjugates and particles and formulations thereof
ActiveUS20170095569A1Reduce deliveryImproved biodistributionHeavy metal active ingredientsOrganic active ingredientsCancer preventionActive agent
Nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker have been designed. Such nanoparticles and microparticles can provide improved temporospatial delivery of the active agent and / or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.
Owner:TVA (ABC) LLC
Antibody mimic conjugates and particles
InactiveUS20190085034A1Reduce deliveryImproved biodistributionPolypeptide with localisation/targeting motifPowder deliveryDiagnostic agentActive agent
Particles, including nanoparticles and microparticles, and pharmaceutical formulations thereof, comprising conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety via a linker have been designed which can provide improved temporospatial delivery of the active agent and / or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.
Owner:TVA (ABC) LLC
Compositions and methods for generating and screening adenoviral libraries
ActiveUS9018138B2Promote generationReduce binding and infection rateUltrasonic/sonic/infrasonic diagnosticsVirusesBiologyDNA
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Hsp90 targeted conjugates and particles and formulations thereof
ActiveUS20190054072A1Reduce deliveryImproved biodistributionOrganic active ingredientsPharmaceutical non-active ingredientsDiagnostic agentMedicine
Conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to an HSP90 targeting moiety via a linker have been designed. Nanoparticles and microparticles comprising such conjugates can provide improved temporospatial delivery of the active agent and / or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or other diseases.
Owner:TVA (ABC) LLC
Targeted conjugates and particles and formulations thereof
ActiveUS9750818B2Reduce deliveryImproved biodistributionBiocideOrganic active ingredientsDiagnostic agentNanoparticle
Owner:TVA (ABC) LLC
Isolated polypeptides and methods of improving muscle strength
ActiveUS8309068B2Altered binding characteristicsImproved biodistributionNervous disorderAntipyreticMyostatinMuscle strength
An isolated recombinant polypeptide having myostatin antagonist activity, comprising a C-terminally truncated mature myostatin peptide, wherein the C-terminal truncation is at a position at or between amino acids 281 and 329, or a fragment, variant or derivative thereof.
Owner:MYOSTIN THERAPEUTICS PTY LTD
Liposome co-carrying CD73 antibody and doxorubicin and its preparation method and application
ActiveCN113440610BImproved biodistributionExert anti-tumor effectOrganic active ingredientsAntibody ingredientsPhospholipinLipofectamine
The present invention provides liposomes co-carrying CD73 antibody and doxorubicin and its preparation method and application, wherein, the liposomes co-carrying CD73 antibody and doxorubicin is a lipid core coated with doxorubicin, The CD73 antibody is modified outside the lipid core, and the CD73 antibody is modified on the surface of the lipid core by coupling to the phospholipid PEG active ester micelles. The liposomes co-carrying CD73 antibody and doxorubicin provided by the invention reduce the drug resistance and side effects of doxorubicin in the treatment of triple-negative breast cancer, improve the biodistribution of doxorubicin in the body, and increase the bioavailability , and reversed the immune microenvironment in the tumor of triple-negative breast cancer, turning it into a hot tumor, and achieved a better therapeutic effect on triple-negative breast cancer.
Owner:SHANDONG UNIV
Myostatin antagonists
ActiveUS20090324590A1Good treatment effectQuality improvementNervous disorderAntipyreticPeptideMyostatin
An isolated recombinant polypeptide having myostatin antagonist activity, comprising a C-terminally truncated mature myostatin peptide, wherein the C-terminal truncation is at a position at or between amino acids 281 and 329, or a fragment, variant or derivative thereof.
Owner:MYOSTIN THERAPEUTICS PTY LTD
Double-stranded nucleic acid compounds
ActiveUS20150259676A1Decreasing silencing of an inadvertent targetImprove efficacySugar derivativesPharmaceutical non-active ingredientsDouble strandOrganic chemistry
Owner:QUARK FARMACUITIKALS INC
Peptide-Based Compounds and Their Uses for Tumor Imaging and Targeting
InactiveUS20170128596A1High tumor-to-background contrastStrong tumor-specific signal intensityCompound screeningApoptosis detectionAbnormal tissue growthTumor targeting
The present invention relates to peptide-based compounds comprising (i) at least one peptide comprising the amino acid sequence of TKDNNLLGRFELXG wherein X is S or T and (ii) at least one label and / or drug. The present invention further relates to the use of said peptide-based compounds for tumor imaging and / or tumor targeting. The present invention further relates to the use of said peptide-based compounds as carrier of tumor therapeutic(s). The present invention further relates to methods for the in vitro and / or in vivo visualization, identification and / or detection of tumor cells and / or metastases as well as to methods for the treatment of cancer. The present invention further relates to a screening method for anti-tumor compounds.
Owner:KLINIKUM REKHTS DER IZAR DER TEKHNISHEN UNIV MYUNKHEN +1
Sstr-targeted conjugates and particles and formulations thereof
ActiveUS20190262460A1Reduce deliveryImproved biodistributionOrganic active ingredientsReceptors for hormonesActive agentSomatostatin receptor binding
Conjugates of an active agent such as DM1 attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and / or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.
Owner:TVA (ABC) LLC
Sstr-targeted conjugates and particles and formulations thereof
ActiveUS20180221499A1Reduce deliveryImproved biodistributionOrganic active ingredientsPowder deliveryCancer preventionActive agent
Conjugates of an active agent such as DM1 attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and / or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.
Owner:TVA (ABC) LLC
RNA Modulating Oligonucleotides with Improved Characteristics for the Treatment of Duchenne and Becker Muscular Dystrophy
ActiveUS20190194656A1High affinityHigh melting temperatureSplicing alterationMuscular disorderMuscular dystrophyBiochemistry
Owner:BIOMARIN TECH BV
Methods of use of sphingolipid polyalkylamine oligonucleotide compounds
InactiveUS20160208247A1Increased cellular uptakeExtended circulation timeSugar derivativesSpecial deliverySphingolipid metabolismMedicinal chemistry
Provided herein are sphingolipid-polyalkylamine siRNA compounds pharmaceutical compositions comprising such compounds, and methods of use in therapy.
Owner:QBI ENTERPRISES
HSP90 targeted conjugates and particles and formulations thereof
ActiveUS10548881B2Reduce deliveryImproved biodistributionOrganic active ingredientsPharmaceutical non-active ingredientsCancer preventionDisease
Conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to an HSP90 targeting moiety via a linker have been designed. Nanoparticles and microparticles comprising such conjugates can provide improved temporospatial delivery of the active agent and / or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or other diseases.
Owner:TVA (ABC) LLC
Liposome co-loaded with CD73 antibody and adriamycin, and preparation method and application of liposome
ActiveCN113440610AImproved biodistributionExert anti-tumor effectOrganic active ingredientsAntibody ingredientsAntiendomysial antibodiesTherapeutic effect
The invention provides a liposome co-loaded with CD73 antibody and adriamycin, and a preparation method and application of the liposome. A lipid core coated with the adriamycin is arranged in the liposome co-loaded with the CD73 antibody and the adriamycin, the outside of the lipid core is modified with the CD73 antibody, and the CD73 antibody is coupled to a phospholipid PEG active ester micelle and then is modified on the surface of the lipid core. The lipidosome co-loaded with the CD73 antibody and the adriamycin reduces the drug resistance and the toxic and side effects of the adriamycin in treatment of the triple negative breast cancer, improves in-vivo biological distribution of the adriamycin, improves bioavailability, and turns an immune microenvironment in a triple negative breast cancer tumor, so that the triple negative breast cancer tumor is converted into a thermal tumor, and a relatively good treatment effect for the triple negative breast cancer is realized.
Owner:SHANDONG UNIV
Targeted conjugates and particles and formulations thereof
InactiveUS20190125888A1Reduce deliveryImproved biodistributionOrganic active ingredientsPowder deliveryMedicineActive agent
Nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as maytansinoid attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker have been designed. Such nanoparticles and microparticles can provide improved temporospatial delivery of the active agent and / or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided.
Owner:TVA (ABC) LLC
Sphingolipid-polyalkylamine-oligonucleotide compounds
ActiveUS9889200B2Increased cellular uptakeFacilitated releaseSpecial deliveryGenetic material ingredientsSphingolipid metabolismPhosphoramidite
Owner:QBI ENTERPRISES +1
Hsp90 targeted conjugates and particle formulations thereof
InactiveUS20200237746A1Reduce deliveryImproved biodistributionOrganic active ingredientsPharmaceutical non-active ingredientsCancer preventionDisease
Conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to an HSP90 targeting moiety via a linker have been designed. Nanoparticles and microparticles comprising such conjugates can provide improved temporospatial delivery of the active agent and / or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or other diseases.
Owner:TVA (ABC) LLC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com